Peking University Third Hospital (Peking University Third Clinical Medical College)

A multicenter, single-arm, open-label, phase Ib/II study conducted in China evaluated JMT103 in patients with unresectable or surgically-challenging giant cell tumor of bone (GCTB). The study, approved by ethics committees and registered at ClinicalTrials.gov (NCT04255576), involved 24 centers and administered JMT103 subcutaneously at 2 mg/kg every four weeks. Primary endpoints included histopathological or radiological objective tumor response (OTR), with secondary endpoints covering overall response rate (ORR), disease control rate (DCR), time to progression (TTP), and safety. Statistical analyses were performed using SAS software, with a sample size of 125 patients to ensure a 95% confidence interval for OTR.

FDA grants breakthrough therapy designation to Simcere's edaravone and dexborneol sublingual tablets (Sanbexin) for acute ischemic stroke, based on TASTE-SL phase 3 study data showing improved functional outcomes within 48 hours. The study, led by Dongsheng Fan, demonstrated a 64.4% good functional outcome rate in treated patients vs 54.7% in placebo, with similar safety profiles. Craig S. Anderson highlights the potential implications of this low-cost, easily administered treatment, though its relevance may be limited to Chinese populations.

Bladder cancer's complexity arises from genetic mutations, oncogene activation, and tumor suppressor gene inactivation. Its heterogeneity complicates treatment, with surgery and chemotherapy being primary options. Recent genomic research aims to improve diagnosis, treatment strategies, and understand chemosensitivity differences among patients.